Gilead Sciences

@GileadSciences · Foster City, California · joined 02 Jun 2011

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. Read more: https://t.co/TZWHS6iRTe

72 326Followers

198Following

4 667Posts total

14.6KViews on collected posts

Against accounts of the same size

7 posts from the last 90 days, next to the 10K–100K follower range. below its peers on both reach and engagement.

Median views1 647this account2 747median for 10K–100K

Reach, %2.28%this account8.35%median for 10K–100K

Engagement, %0.64%this account1.45%median for 10K–100K

Metric	This account	Median for 10K–100K	Ratio
Median views per post	1 647	2 747	0.60×
Reach (views ÷ followers)	2.28%	8.35%	0.27×
Engagement rate	0.64%	1.45%	0.44×

Others in this range → Compare with another account → How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.5K24 Jul

371 Aug

312 Aug

2.6K4 Aug

1.6K24 Aug

5.3K27 Aug

1.6K28 Aug

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.64%24 Jul

2.70%1 Aug

3.23%2 Aug

0.39%4 Aug

0.43%24 Aug

0.72%27 Aug

0.44%28 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.45%.

What the audience does

Likes65.2%58 in total

Reposts15.7%14 in total

Replies12.4%11 in total

Quotes3.4%3 in total

Bookmarks3.4%3 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Latest posts

We’re honored to receive the 2026 ACS Heroes of Chemistry Award at #ACSFall2026 – reflecting years of antiviral chemistry and our commitment to advancing science that benefits patients. Learn more about our R&D approach: https://t.co/TsWS7CTMgR https://t.co/siofZziIDM 1.6K views · 5 likes · 1 reposts · 1 replies 28 Aug 2026 #GileadNews: The U.S. FDA approves first and only single-tablet regimen for the treatment of HIV in adults who are virologically suppressed, including those on complex multi-tablet regimens. Learn more: https://t.co/ZzAqXVm6Qe https://t.co/YvFPdwpYIz 5.3K views · 26 likes · 7 reposts · 2 replies 27 Aug 2026 #GileadNews: The European Commission (EC) expands role of our treatment for first-line metastatic triple-negative breast cancer (mTNBC), establishing it as the first and only antibody-drug conjugate for first-line treatment across PD-(L)1 status. https://t.co/qf94xxeTbG https://t 1.6K views · 5 likes · 2 reposts · 0 replies 24 Aug 2026 #GileadNews: Today, Gilead announced second quarter 2026 results, including 10% year-over-year growth in our base business. Read more, including important cautionary statements about forward-looking information, here: https://t.co/m0775laYO1 https://t.co/pycs49jUIT 2.6K views · 6 likes · 1 reposts · 3 replies 04 Aug 2026 @GileadSciences Monsters https://t.co/ZxQs3lHCdR 31 views · 1 likes · 0 reposts · 0 replies 02 Aug 2026 @GileadSciences #quebradepatentesja 37 views · 1 likes · 0 reposts · 0 replies 01 Aug 2026 #GileadNews: We received a #CHMP positive opinion for our combination regimen in PD-(L)1-positive first-line metastatic triple-negative breast cancer. If approved, patients with PD-(L)1 positive mTNBC will have a new treatment option in Europe. https://t.co/RYU4enosT1 https://t.c 3.5K views · 14 likes · 3 reposts · 5 replies 24 Jul 2026